2+ hour, 14+ min ago   (570+ words) FDA grants Priority Review for gedatolisib, a promising treatment for advanced HR+/HER2- breast cancer, showcasing significant efficacy in recent trials. The FDA has formally accepted the New Drug Application (NDA) for gedatolisib (PF-05212384, PKI-587; Celcuity) in the treatment of hormone…...